Compare Inovio Pharmaceuticals Inc (INO) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Norwegian Cruise Line Holdings Ltd trades at $19.57 (market cap $8.95B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 100.3× Inovio Pharmaceuticals Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | NCLH | |
|---|---|---|
Market Cap | $89.27M | $8.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $26.94 |
52-Week Low | $1.05 | $14.79 |
Enterprise Value | $60.28M | $23.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Norwegian Cruise Line Holdings (NCLH) trades at $19.47, showing minimal daily movement with a 0.05% gain. The stock demonstrates strong fundamental momentum with three consecutive quarterly earnings beats and improving profitability metrics. Recent technical indicators show mixed signals with a bearish overall trend but neutral oscillators. The company maintains solid revenue growth, reaching $9.83 billion in 2025, while navigating significant capital expenditures for fleet expansion.
NCLH presents a compelling value opportunity with attractive valuation ratios (P/E: 15.69, P/S: 0.94) and strong analyst support (55.55% buy ratings). However, investors face risks from high debt levels ($13.1 billion total debt) and sensitivity to macroeconomic factors affecting travel demand. The upcoming Q2 2026 earnings report on July 30 represents a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
